Heather Verba is an experienced professional with a background in research and development, manufacturing, and customer service. Currently serving as a Research and Development Technician at ProKidney Corp. since August 2022, Heather previously held the position of Manufacturing Specialist at ProKidney from July 2021 to August 2022. Prior experience includes an externship at BRITE, North Carolina Central University, and roles at Bennett & West, PLLC and Hampton, where Heather demonstrated skills in administration and customer service. Heather holds an Associate's degree in General Education from Surry Community College and has furthered studies at Forsyth Technical Community College from 2020 to 2022.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.